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Aging is associated with structural and functional changes in the vasculature, including
endothelial dysfunction, arterial stiffening and remodeling, impaired angiogenesis, and
defective vascular repair, and with increased prevalence of atherosclerosis. Cardiovas-
cular risk is similar for older men and women, but lower in women during their fertile
years.This age- and sex-related difference points to estrogen as a protective factor because
menopause is marked by the loss of endogenous estrogen production. Experimental and
some clinical studies have attributed most of the protective effects of estrogen to its
modulatory action on vascular endothelium. Estrogen promotes endothelial-derived NO
production through increased expression and activity of endothelial nitric oxide synthase,
and modulates prostacyclin and thromboxane A2 release. The thromboxane A2 pathway
is key to regulating vascular tone in females. Despite all the experimental evidence,
some clinical trials have reported no cardiovascular beneﬁt from estrogen replacement
therapy in older postmenopausal women. The “Timing Hypothesis,” which states that
estrogen-mediated vascular beneﬁts occur only before the detrimental effects of aging
are established in the vasculature, offers a possible explanation for these discrepancies.
Nevertheless, a gap remains in current knowledge of cardiovascular aging mechanisms
in women. This review comprises clinical and experimental data on the effects of aging,
estrogens, and hormone replacement therapy on vascular function of females.We aim to
clarify how menopause and aging contribute jointly to vascular aging and how estrogen
modulates vascular response at different ages.
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INTRODUCTION
Cardiovascular disease (CVD) is the leading cause of mortality
in both men and women in developed countries. Nonetheless,
sex-associated differences regarding the age of CVD onset and its
progression are observed worldwide. Incidence of CVD in pre-
menopausal women is markedly lower than age-matched men in
epidemiological studies (Messerli et al., 1987; Bairey Merz et al.,
2006; Shaw et al., 2006). After menopause, however, the incidence
is comparable or even higher in women than in men (Lerner and
Kannel,1986; Eaker et al., 1993),makingCVD theprimary cause of
death in postmenopausal women (55 versus 43% in men), exceed-
ing all cancer deaths (Rosamond et al., 2008). The lower CVD
risk among fertile women is often attributed to the protective role
of estrogens at the vascular level. According to epidemiological
observations and extensive basic research, estrogen and other sex
steroids have direct cardiovascular beneﬁts. Estrogen modulates
a myriad of molecular pathways that improve vascular function,
whether at the physiological level or when administered as hor-
mone replacement therapy (HRT; Grodstein et al., 2000, 2001;
Miller and Duckles, 2008).
Nevertheless, some clinical studies have questioned the pro-
tective value of HRT against vascular disease. Two randomized
clinical trials, the Women’s Health Initiative (WHI; Rossouw et al.,
2002) and the Heart and Estrogen/Progestin Replacement Study
(HERS I and II; Gambacciani et al., 2002), indicate that HRT
may increase CVD risk and events in postmenopausal women.
The reason for this paradox could be attributable to many patient
characteristics, including age.
Although aging occurs progressively in both men and women,
the onset of menopausemarks a sudden increase in the appearance
of aging-associated signs in women, and more speciﬁcally in the
progress of vascular aging. Information about the role of age and
menopause in the development of CVD in women is scarce. This
review of clinical and experimental data on the effects of aging,
estrogens, and HRT on vascular function of females aims to clarify
how menopause and aging contribute jointly to vascular aging and
how estrogen modulates vascular response at different ages.
HOW DO ESTROGENS AFFECT VASCULAR FUNCTION?
The numerous vascular effects of estrogens are triggered by com-
plex genomic and non-genomic mechanisms. They include mod-
ulation of vascular function and inﬂammatory response as well
as metabolic and hemodynamic effects. Estradiol, the most abun-
dant and potent estrogen in humans, mainly binds and activates
estrogen receptors (ERs). Vascular estrogen signaling involves at
least three ERs identiﬁed in both vascular smooth muscle and
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endothelium, reinforcing the idea that estrogen has a key role in
controlling vascular function. The classical subtypes ERα (Soloff
and Szego, 1969) and ERβ (Kuiper et al., 1996) vary not only in
their tissue distributions, but also in their agonist/antagonist pro-
ﬁle with respect to several compounds (Cano and Hermenegildo,
2000). These ER subtypes belong to the intracellular receptors
classically deﬁned as nuclear ligand-activated transcription fac-
tors. Activation of these receptors by the corresponding hormones
affects gene expression by acting on estrogen-response elements
in the target genes and modulating transcriptional events (Beato
et al., 1995). Estrogen binding to ERα and ERβ regulates gene
expression in a time- and tissue-dependent manner, generating
controversy about the type of receptor involved in vascular pro-
tection (Murphy, 2011). In the cardiovascular system, both ERα
and ERβ have been identiﬁed in the endothelium, smooth mus-
cle cells, adventitia, and adrenergic nerve endings of arteries from
various territories and several species, including humans (Karas
et al., 1994; Kim-Schulze et al., 1996; Venkov et al., 1996; Register
and Adams, 1998). Although it has been reported that cultured
endothelial cells do not express ERα (Toth et al., 2009), other
investigators have demonstrated the presence of both ERα and
ERβ mRNA in endothelium (Wagner et al., 2001) and data from
our group demonstrate the protein expression of both ERα and
ERβ in HUVEC (Sobrino et al., 2009, 2010).
In addition to their classic nuclear location, ER can also tar-
get the plasma membrane, enabling estrogen activation of several
signaling pathways, including those involved in calcium mobiliza-
tion (Zhang et al., 1994; Nakajima et al., 1995; Prakash et al., 1999)
and the phosphatidylinositol-3-kinase (PI3K) pathway (Hisamoto
et al., 2001). A third type of ER, G-protein coupled, and mainly
located in the plasma membrane, was initially named GPR30
(Takada et al., 1997), then renamed GPER by the International
Union of Basic and Clinical Pharmacology, IUPHAR (Alexan-
der et al., 2008). GPER is expressed in both endothelial and
smooth muscle cells of human arteries and veins (Haas et al., 2007;
Deschamps and Murphy, 2009). After estrogen binding, GPER
activates rapid signaling cascades such as extracellular signal-
related kinase and PI3K (Meyer et al., 2011). Several rapid and
non-genomic estrogen effects formerly attributed toERαhavenow
been described as GPER-mediated (Prossnitz and Barton, 2011).
The vascular protection conferred by estrogen may be medi-
ated indirectly by its inﬂuence on the metabolism of lipoproteins
or by a direct action on the modulation of molecular path-
ways in the vessel wall, and more speciﬁcally on endothelial cells
(Hermenegildo et al., 2002). Vascular endothelium not only reg-
ulates vascular tone through ﬂow-mediated mechanisms, but also
confers antithrombotic and antiinﬂammatory properties to the
blood vessel. Nitric oxide (NO), the primary endothelial-derived
mediator, is involved in many physiological processes, including
vasodilation and inhibition of thrombosis, cell migration, and
proliferation (Dudzinski and Michel, 2007; Lamas et al., 2007;
Michel and Vanhoutte, 2010). Estrogen is known to increase NO
bioavailability by mechanisms that either directly increase NO
generation (Figure 1) or decrease superoxide anion (O−2 ) con-
centration, thereby attenuating O−2 -mediated NO inactivation.
Mechanisms involved in estrogen-induced increases in NO avail-
ability include: (1) transcriptional stimulation of endothelial NO
synthase (eNOS) gene expression (Huang et al., 1997; Sumi and
Ignarro, 2003); (2) non-genomic activation of enzyme activity via
a PI3K/phosphokinase B (PKB/AKT)-mediated signaling pathway
(Hisamoto et al., 2001); (3) increased intracellular free Ca2+ con-
centration ([Ca2+]i) in endothelial cells (Rubio-Gayosso et al.,
2000); (4) decreased production of asymmetric dimethylarginine
(ADMA), the eNOS endogenous inhibitor (Monsalve et al., 2007);
and (5) attenuated O−2 concentrations (Wassmann et al., 2001;
Dantas et al., 2002; Ospina et al., 2002).
Estrogens such as 17β-estradiol, estrone, and estriol have been
described to act as reactive oxygen species (ROS) scavengers by
virtue of the hydrogen-donating capacity of their phenolic molec-
ular structure (Halliwell and Grootveld, 1987; Dubey and Jackson,
2001). However, in these studies the direct effect of estrogens as
scavengers can only be observed at concentrations above 1μM
(Arnal et al., 1996; Kim et al., 1996). Considering that plasma
concentrations of estrogen in physiological conditions are within
the nanomolar range, it is likely that direct scavenger action is
not estrogen’s main antioxidant mechanism. Estrogen modulates
ROS concentration through a mechanism that involves interac-
tion with its estrogenic nuclear receptors to decrease oxidative
proteins and/or increase antioxidant enzymes expression. Many
studies have associated changes in estrogen levels with altered
levels of antioxidant enzymes including glutathione peroxidase,
catalase, and superoxide dismutase (Capel et al., 1981; Robb and
Stuart, 2011; Sivritas et al., 2011). Moreover, estrogen modulates
NADH/NADPH oxidases and AT1 receptor gene expression, both
of which are major sources of O−2 production (Wassmann et al.,
2001; Dantas et al., 2002).
Estrogen also has a modulating effect on constrictive factors
and positively upregulates the production of endothelium-derived
relaxing factors such as PGI2 (Sobrino et al., 2009, 2010) and
the endothelium-derived hyperpolarizing factors (Golding and
Kepler, 2001), both of which are important mediators of vas-
cular relaxation in resistance-sized arteries. The beneﬁcial effects
of estrogen on the endothelium can be partially explained by an
inhibitory effect on the production or action of the cyclooxygenase
(COX)-derived vasoconstrictor agents prostaglandin H2, PGH2,
and thromboxane A2, TXA2 (Davidge and Zhang, 1998; Dantas
et al., 1999; Novella et al., 2010), and of endothelin-1 (ET-1; David
et al., 2001).
Furthermore, estrogen can interfere with ion channels through
non-genomic actions. It regulates contractile responses by a direct
modulation of Ca2+ mobilization into the vascular smooth mus-
cle cells. Direct interaction of estradiol with voltage-gated Maxi-K
channel subunit beta, which confers higher Ca2+ sensitivity, may
modulate vascular smooth muscle (Valverde et al., 1999). Estro-
gen does not inhibit Ca2+ release from the intracellular stores
(Crews and Khalil, 1999; Murphy and Khalil, 1999). However,
supraphysiological concentrations of estrogen impedeCa2+ inﬂux
from the extracellular space (Han et al., 1995; Crews and Khalil,
1999; Murphy and Khalil, 1999) by inhibiting Ca2+ entry through
voltage-gated Ca2+ channels (Freay et al., 1997; Kitazawa et al.,
1997; Crews and Khalil, 1999; Murphy and Khalil, 1999). Expres-
sion of the L-type Ca2+ channels in cardiac muscle is substantially
increased in ER-deﬁcient mice (Johnson et al., 1997), suggesting
ER-mediated regulation of Ca2+ mobilization.
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FIGURE 1 | Dual effects of estradiol (E2) on eNOS expression and
activity. Estradiol effects on eNOS-mediated nitric oxide (NO) production
include both genomic and non-genomic effects. Genomic effects include
the classical intracellular estrogen receptors (ER), which after binding of E2
interact with estrogen-response element (ERE) in DNA, resulting in an
increased eNOS expression. Moreover, E2 binding to GPER leads to
activation of different transcriptional factors such as cAMP response
element (CRE) which also induces eNOS expression. Among non-genomic
effects, ER and GPER regulate the E2-induced eNOS activity (modiﬁed
from Sobrino, 2011).
Estrogen also exerts direct modulation on the components of
the renin-angiotensin system (RAS), a key regulator of blood pres-
sure and smooth muscle cell growth. Production of angiotensin II
(Ang II), the active hormone of the RAS, is reduced by estrogen
inhibition of angiotensin-converting enzyme (ACE) expression.
In animal models of menopause and in postmenopausal women,
chronic estrogen replacement reduces ACE activity in the circu-
lation and in tissues including the kidney and aorta (Brosnihan
et al., 1999; Seely et al., 2004). Furthermore, estrogen attenuates
expression of and tissue response to type 1 angiotensin receptor
(AT1) in the aorta, heart, and kidney (Silva-Antonialli et al., 2000;
Wu et al., 2003).
THE PROCESS OF VASCULAR AGING: HOW ARE FEMALES
AFFECTED?
Vascular aging is associated with endothelial dysfunction, arte-
rial stiffening and remodeling, impaired angiogenesis, defective
vascular repair, and an increasing prevalence of atherosclerosis
(Lakatta and Levy, 2003; Erusalimsky, 2009). Aging-associated
changes in structure and function of large elastic arteries are
seen even in the absence of clinical CVD (Moreau et al., 2003).
Although aging per se has detrimental effects in the vasculature,
the lack of estrogen due to menopause may add an aggravating
CVD risk factor in women, compared to arterial aging in men.
In middle-aged females, aging-associated vascular dysfunction is
potentiated by lack of estrogen due to menopause or ovariec-
tomy and improves with estrogen replacement (Harman, 2004;
Stice et al., 2009; Novella et al., 2010). Unfortunately, the onset
of menopause coincides with a time when aging-associated dam-
age may be noted, making it particularly difﬁcult to distinguish
between the contributions of aging and the lack of estrogen.
Vascular aging is a natural phenomenon that could be simply
described as a consequence of physical stress, beginning early in
life. Arteries are elastic tissues, susceptible to fatigue, and frac-
ture over time as a consequence of extension-relaxation cycles
during heartbeats (Avolio et al., 1983). In cross-sectional stud-
ies, postmenopausal females taking HRT have less arterial stiffness
than their non-treated peers (Moreau et al., 2003; Sumino et al.,
2005, 2006). Radial artery distensibility ﬂuctuates in accordance
with estrogen levels during menstrual cycles (Giannattasio et al.,
1999). Basic research using animal models of estrogen withdrawal
and aging suggests a modulatory role for estrogen in the mol-
ecular mechanisms to prevent arterial stiffening (Zhang et al.,
2000). A recent study reported that HRT improves arterial com-
pliance, an effect related in part to estrogen actions in the control
of endothelial-dependent vasodilatory tone (Moreau et al., 2012).
Collagen and elastin content of arterial walls is a key factor in
arterial thickening and stiffening. It is mostly regulated by matrix
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metalloproteinases (MMP), enzymes capable of degrading com-
ponents of the extracellular matrix. During aging, MMP activity
decreasesmarkedly, collagen accumulates, and stiffening increases.
Estrogen replacement in ovariectomized rats increasesMMPactiv-
ity and restores aged arteries to structural properties similar to
those of younger animals studied (Zhang et al., 2000).
Aging is also associated with biochemical changes implicated in
CVDdevelopment andprogression.Dysfunctionof both endothe-
lial and smooth muscle molecular signaling appears during the
aging process and favors vasospasm, thrombosis, inﬂammation,
and abnormal cell migration and proliferation (Lakatta and Levy,
2003; Briones et al., 2005; Barton, 2010; Herrera et al., 2010).
Endothelial dysfunction in the elderly has been associated with
malfunctioning of vascular tissue, resulting in atherosclerosis,
hypertension, and coronary artery disease (Lakatta and Levy, 2003;
Herrera et al., 2010), renal dysfunction (Schmidt et al., 2001; Erdely
et al., 2003), and Alzheimer disease (Price et al., 2004). In women,
a slight age-related decrease in endothelium-dependent relaxation
persists until middle age (around 50 years). After that, the declin-
ing response to the endothelium-dependent vasodilator hastens,
even exceeding the rate experienced by men (Taddei et al., 1996).
The mechanisms for age-associated endothelial dysfunction
are multiple, although most are associated with decreased NO
bioavailability (Hayashi et al., 2008; Santhanamet al., 2008; Erusal-
imsky, 2009; Kim et al., 2009). Reduced endothelium-dependent
and NO-mediated vasodilation has been described in both human
and animal models of aging (Kim et al., 2009; Virdis et al., 2010).
Lower NO production in the elderly may be based on decreased
NO synthesis or increased NO degradation. Suggested mecha-
nisms to explain reduced NO production include: (1) decreased
expression of eNOS (Briones et al., 2005; Yoon et al., 2010); (2) a
lack of NO precursor (l-arginine; Santhanam et al., 2008) and
eNOS cofactor tetrahydrobiopterin (BH4; Yoshida et al., 2000;
Eskurza et al., 2005; Meyer et al., 2011); and (3) increased endoge-
nous eNOS inhibitor ADMA (Xiong et al., 2001; Kielstein et al.,
2003). On the other hand, strong evidences support the hypothe-
sis that age-associated increase in oxidative stress and consequent
productionof O−2 is a potent contributor to lowerNObioavailabil-
ity and increased endothelial dysfunction (Jacobson et al., 2007;
Rodriguez-Manas et al., 2009). There is little information to corre-
late the progression of aging with the production/degradation of
NO in women. Although several studies have described decreased
expression of eNOS in senile female rats and mice (Wynne et al.,
2004; Novensa et al., 2011), aging-associated effects on eNOS in
women can be easily confounded with the effects of lack of estro-
gen, since most of these studies grouped women into just two
time-points: premenopausal and menopausal groups.
Even though the decline inNObioavailability could sufﬁciently
explain most of the changes in the functioning of vascular cells,
other molecules crucial to control of vascular function are also
modiﬁed by aging. In the regulation of vascular tone,COX-derived
factors are particularly important as they can induce both vascular
relaxation (PGI2) and contraction (TXA2 and PGH2). Some stud-
ies have reported a prevalence in the production of relaxing COX
factors in the vasculature of young and healthy individuals (Tang
and Vanhoutte, 2008). With aging, COX-dependent vasoconstric-
tors production becomes evident, leading to increased vascular
contraction (Taddei et al., 1997; Rodriguez-Manas et al., 2009).
However, the COX isoform involved in the generation of contrac-
tile prostanoids remains unclear. In functional studies developed
in femoral arteries of aged rats, oxygen free radicals participate
in the augmented endothelium-dependent contractions mediated
by COX-derived prostanoids. Both the constitutive and inducible
isoforms of COX contribute to this endothelial dysfunction (Shi
et al., 2008). Molecular studies performed in endothelial cells from
aged rats showed an increase in mRNA levels of COX-1, COX-
2, and other enzymes involved in the synthesis of prostanoids
(Tang andVanhoutte, 2008), demonstrating the importance of the
arachidonic acid–COXcascade in the endothelial and vascular dys-
function associated with aging. Moreover, functional studies have
demonstrated an interaction between NO and prostanoids path-
ways. In aorta from aged female mice,NO bioavailability increases
when the COX pathway is inhibited; both gene and protein expres-
sion of COX-1 are increased (Novella et al., 2011). Furthermore,
activation of inﬂammatory pathways in the vascular wall plays a
central role in the process of vascular aging.
Even in the absence of traditional risk factors for atherosclero-
sis, an age-associated shift to a proinﬂammatory gene expression
proﬁle, known as endothelial activation, induces upregulation
of cellular adhesion molecules and cytokines, which increases
endothelial–leukocyte interactions and permeability, mechanisms
considered crucial to initial steps in the development of athero-
sclerosis (Herrera et al., 2010; Seals et al., 2011). Accordingly, a
sex-associated difference in inﬂammatory responses during aging
has been proposed. Inﬂammatory atherosclerosis and associated
acute coronary heart disease develop earlier in life in men than in
women (Roger et al., 2011) and are associated with earlier death,
although men and women present the same overall plaque bur-
den (Frink, 2009). In animal models of atherosclerosis, male sex
contributes to a faster and more severe progression of lipid depo-
sition, remodeling, and aortic lesions (Pereira et al., 2010; Surra
et al., 2010).
COULD ESTROGEN DECREASE VASCULAR AGING IN
WOMEN?
With the wide-ranging data from experimental research, estro-
gens might appear to promise protection against the progression
of vascular aging and CVD in women. Epidemiological observa-
tional studies also suggest that postmenopausal women on HRT
are less likely to develop CVD than non-users at the same age
(Grodstein et al., 2000, 2001) Nevertheless, these studies contrast
with the large prospective clinical trials, HERS and WHI, which
failed to show reduced cardiovascular events in postmenopausal
women on HRT. In fact, WHI suggested that HRT was associated
with increased risk to the cardiovascular system (Rossouw et al.,
2002). Possible reasons for this discrepancy have been extensively
discussed and include the average age of women entering most
HRT clinical trials, 65 years and older, which results in a study
population with some degree of aging-associated vascular dam-
age. In addition, participants had been estrogen-deﬁcient for an
average of 10 years before starting HRT, a relatively late start that
could modify the status of ERs and molecular signaling so as to
attenuate the beneﬁts of estrogen. For instance, during aging ERs
can undergo posttranslational modiﬁcations such as methylation,
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which decreases their expression and activity.We recently reported
that aging contributes to increased DNA methylation in female
mice aorta, which could be associated with the decrease in the
modulatory effects of estrogen (Novensa et al., 2011).A few clinical
studies also provide evidence for aging-associated dysregulation
of ER methylation and suggest that focal epigenetic changes in ER
could contribute to decreased estrogen activity and to the devel-
opment of atherosclerosis in elderly women (Post et al., 1999; Kim
et al., 2007).
Detailed examination of WHI data reveals that early initia-
tion of estrogen replacement produces more favorable results than
the later average initiation employed in the WHI studies over-
all (Grodstein et al., 2006; Rossouw et al., 2007; Prentice et al.,
2009). These ﬁndings, togetherwith observational studies,have led
scientists to create the so-called“timing hypothesis” that estrogen-
mediated beneﬁts to prevent CVD only occur when treatment is
initiated before the detrimental effects of aging are established
on vascular walls (Harman, 2006). These effects include endothe-
lial dysfunction and pathophysiological actions, such as increased
vascular calciﬁcation and generalized stiffening of the arterial tree
that increase the prevalence of hypertension and atherosclerosis
(Lakatta and Levy, 2003; Erusalimsky, 2009; Kovacic et al., 2011).
Little information is available on whether and how vascular
effects of estrogen are modiﬁed with aging in females. Aging has
been associated with signiﬁcant reductions in the direct estrogen-
mediated mechanisms of vascular relaxation (Wynne et al., 2004;
LeBlanc et al., 2009; Lekontseva et al., 2010) and inﬂammation
(Pechenino et al., 2011). The lack of estrogen responses in these
animal studies was not related to age-associated changes in the
plasma levels of estrogen or activity of ER, but rather to possi-
ble age-related changes in estrogen-mediated signaling pathways
in the vasculature. Modiﬁcations in the ratio between ERα and
ERβ in older female mice are associated with the lack of pro-
tective effects of estrogen on NO production and with a reversal
in its antioxidant effect to a pro-oxidant proﬁle (Novensa et al.,
2011). Moreover, clinical studies have revealed that CVD risk fac-
tors in postmenopausal women were lower among women aged
50–59 years atHRT initiation (Manson et al., 2007; Sherwood et al.,
2007). These studies clearly establish the complexity of estrogen
effects, which may be inﬂuenced by pathophysiological conditions
including aging and subclinical CVD. Despite convincing argu-
ments by the followers of the “timing hypothesis” the potential
extrapolation of the protective effects of estrogen replacement,
well described in young females, to older women remains con-
troversial. The ﬁeld still lacks detailed experimental and clinical
research on the long-term effects of estrogen and how itmodulates
cardiovascular function during aging.
CONCLUSION AND FUTURE DIRECTION
Our society is aging progressively, and increased life expectancy
enhances the risks for diseases associated with the natural fatigue
of the body, including CVD. Despite this undeniable reality, there
is evidence that vascular aging in women does not follow the same
chronology as in men. The vascular protective effects exerted by
estrogens have been proposed as the major reason for reduced
signs of vascular aging and CVD risk in premenopausal women,
compared to men. When natural estrogen withdrawal occurs and
a woman enters her climacteric stage, effects of sudden vascu-
lar aging become evident, leading to vascular dysfunction and
increased risk of a cardiovascular event. The lack of crucial infor-
mation from clinical trials and the discrepancies in the available
data on the regulation of the female cardiovascular system can
lead to inappropriate diagnosis and treatment of CVD in older
women. Women have been treated like men, despite the notable
sex-associated differences in the elements of aging and disease
processes. Much research effort is still needed to understand age-
and sex-related differences in cardiovascular control, establish the
impact of the menstrual cycle and HRT on vascular function, and
propose new therapeutic strategies to improve CVD diagnosis and
treatment and the overall management of vascular senescence in
women.
ACKNOWLEDGMENTS
Supported by the Spanish Ministerio de Ciencia e Inno-
vación, Instituto de Salud Carlos III –FEDER-ERDF (grants
FIS 06/0589, FIS 08/0176 and PI10/00518 and Red HERACLES
RD06/0009/0005), and Consellería de Sanidad, Generalitat Valen-
ciana (grants AP 097/2011, AP 104/2011, and GE 027/2011). The
authors appreciate the review of English grammar and usage by
Elaine Lilly, Ph.D. (Writer’s First Aid).
REFERENCES
Alexander, S. P., Mathie, A., and Peters,
J. A. (2008). Guide to receptors and
channels (GRAC), 3rd edition. Br. J.
Pharmacol. 153(Suppl. 2), S1–S209.
Arnal, J. F., Clamens, S., Pechet, C.,
Negre-Salvayre, A., Allera, C., Giro-
lami, J. P., Salvayre, R., and Bayard,
F. (1996). Ethinylestradiol does not
enhance the expression of nitric
oxide synthase in bovine endothe-
lial cells but increases the release
of bioactive nitric oxide by inhibit-
ing superoxide anion production.
Proc. Natl. Acad. Sci. U.S.A. 93,
4108–4113.
Avolio, A. P., Chen, S. G., Wang, R. P.,
Zhang,C. L., Li,M. F., andO’Rourke,
M. F. (1983). Effects of aging on
changing arterial compliance and
left ventricular load in a northern
Chinese urban community. Circula-
tion 68, 50–58.
Bairey Merz, C. N., Shaw, L. J., Reis, S.
E., Bittner, V., Kelsey, S. F., Olson,
M., Johnson, B. D., Pepine, C. J.,
Mankad, S., Sharaf, B. L., Rogers,
W. J., Pohost, G. M., Lerman, A.,
Quyyumi, A. A., and Sopko, G.
(2006). Insights from the NHLBI-
sponsored women’s ischemia syn-
drome evaluation (WISE) study:
part II: gender differences in pre-
sentation, diagnosis, and outcome
with regard to gender-based patho-
physiology of atherosclerosis and
macrovascular and microvascular
coronary disease. J. Am. Coll. Car-
diol. 47, S21–S29.
Barton, M. (2010). Obesity and aging:
determinants of endothelial cell
dysfunction and atherosclerosis.
Pﬂugers Arch. 460, 825–837.
Beato, M., Herrlich, P., and Schutz, G.
(1995). Steroid hormone receptors:
many actors in search of a plot. Cell
83, 851–857.
Briones, A. M., Montoya, N., Giraldo,
J., and Vila, E. (2005). Ageing affects
nitric oxide synthase, cyclooxyge-
nase and oxidative stress enzymes
expression differently in mesenteric
resistance arteries. Auton. Autacoid
Pharmacol. 25, 155–162.
Brosnihan, K. B., Senanayake, P. S.,
Li, P., and Ferrario, C. M. (1999).
Bi-directional actions of estro-
gen on the renin-angiotensin sys-
tem. Braz. J. Med. Biol. Res. 32,
373–381.
Cano, A., and Hermenegildo, C. (2000).
Modulation of the oestrogen recep-
tor: a process with distinct suscep-
tible steps. Hum. Reprod. Update 6,
207–211.
Capel, I. D., Jenner, M., Williams, D.
C., Donaldson, D., and Nath, A.
(1981). The effect of prolonged
oral contraceptive steroid use on
erythrocyte glutathione peroxidase
activity. J. Steroid Biochem. 14,
729–732.
www.frontiersin.org June 2012 | Volume 3 | Article 165 | 5
Novella et al. Vascular aging in women
Crews, J. K., and Khalil, R. A. (1999).
Antagonistic effects of 17b-estradiol,
progesterone, and testosterone on
Ca2+ entry mechanisms of coro-
nary vasoconstriction. Arterioscler.
Thromb. Vasc. Biol. 19, 1034–1040.
Dantas, A. P., Scivoletto, R., Fortes,
Z. B., Nigro, D., and Carvalho, M.
H. (1999). Inﬂuence of female sex
hormones on endothelium-derived
vasoconstrictor prostanoid gener-
ation in microvessels of sponta-
neously hypertensive rats. Hyperten-
sion 34, 914–919.
Dantas, A. P., Tostes, R. C., Fortes, Z.
B., Costa, S. G., Nigro, D., and Car-
valho,M.H. (2002). In vivo evidence
for antioxidant potential of estro-
gen in microvessels of female spon-
taneously hypertensive rats. Hyper-
tension 39, 405–411.
David, F. L., Carvalho, M. H., Cobra, A.
L., Nigro, D., Fortes, Z. B., Reboucas,
N.A., and Tostes,R. C. (2001). Ovar-
ian hormones modulate endothelin-
1 vascular reactivity and mRNA
expression in DOCA-salt hyperten-
sive rats. Hypertension 38, 692–696.
Davidge, S. T., and Zhang, Y. (1998).
Estrogen replacement suppresses
a prostaglandin H synthase-
dependent vasoconstrictor in rat
mesenteric arteries. Circ. Res. 83,
388–395.
Deschamps, A. M., and Murphy, E.
(2009). Activation of a novel estro-
gen receptor, GPER, is cardioprotec-
tive in male and female rats. Am.
J. Physiol. Heart Circ. Physiol. 297,
H1806–H1813.
Dubey, R. K., and Jackson, E. K. (2001).
Estrogen-induced cardiorenal pro-
tection: potential cellular, biochemi-
cal, and molecular mechanisms.Am.
J. Physiol. Renal Physiol. 280, F365–
F388.
Dudzinski, D. M., and Michel, T.
(2007). Life history of eNOS: part-
ners and pathways. Cardiovasc. Res.
75, 247–260.
Eaker, E. D., Chesebro, J. H., Sacks, F.
M., Wenger, N. K., Whisnant, J. P.,
and Winston, M. (1993). Cardiovas-
cular disease in women. Circulation
88, 1999–2009.
Erdely, A., Greenfeld, Z., Wagner, L.,
and Baylis, C. (2003). Sexual dimor-
phism in the aging kidney: effects
on injury and nitric oxide system.
Kidney Int. 63, 1021–1026.
Erusalimsky, J. D. (2009). Vascular
endothelial senescence: from mech-
anisms to pathophysiology. J. Appl.
Physiol. 106, 326–332.
Eskurza, I., Myerburgh, L. A., Kahn,
Z. D., and Seals, D. R. (2005).
Tetrahydrobiopterin augments
endothelium-dependent dilatation
in sedentary but not in habitually
exercising older adults. J. Physiol.
568, 1057–1065.
Freay, A. D., Curtis, S. W., Korach, K. S.,
and Rubanyi, G. M. (1997). Mech-
anism of vascular smooth muscle
relaxationby estrogen indepolarized
rat and mouse aorta. Role of nuclear
estrogen receptor and Ca2+ uptake.
Circ. Res. 81, 242–248.
Frink, R. J. (2009). Gender gap, inﬂam-
mation and acute coronary disease:
are women resistant to atheroma
growth? Observations at autopsy. J.
Invasive Cardiol. 21, 270–277.
Gambacciani, M., Rosano, G. M., Mon-
teleone, P., Fini, M., and Genazzani,
A.R. (2002).Clinical relevanceof the
HERS trial. Lancet 360, 641.
Giannattasio, C., Failla, M., Grappiolo,
A., Stella,M. L., Del, B. A., Colombo,
M., and Mancia, G. (1999). Fluc-
tuations of radial artery distensibil-
ity throughout the menstrual cycle.
Arterioscler. Thromb. Vasc. Biol. 19,
1925–1929.
Golding, E. M., and Kepler, T. E.
(2001). Role of estrogen in modu-
lating EDHF-mediated dilations in
the female ratmiddle cerebral artery.
Am. J. Physiol. Heart Circ. Physiol.
280, H2417–H2423.
Grodstein, F., Manson, J. E., Colditz, G.
A., Willett, W. C., Speizer, F. E., and
Stampfer, M. J. (2000). A prospec-
tive, observational study of post-
menopausal hormone therapy and
primary prevention of cardiovascu-
lar disease. Ann. Intern. Med. 133,
933–941.
Grodstein, F., Manson, J. E., and
Stampfer, M. J. (2001). Post-
menopausal hormone use and sec-
ondary prevention of coronary
events in the nurses’ health study.
A prospective, observational study.
Ann. Intern. Med. 135, 1–8.
Grodstein, F., Manson, J. E., and
Stampfer, M. J. (2006). Hormone
therapy and coronary heart disease:
the role of time sincemenopause and
age at hormone initiation. J.Womens
Health (Larchmt.) 15, 35–44.
Haas, E., Meyer, M. R., Schurr, U., Bhat-
tacharya, I., Minotti, R., Nguyen, H.
H., Heigl, A., Lachat, M., Genoni,
M., and Barton, M. (2007). Differ-
ential effects of 17beta-estradiol on
function and expression of estro-
gen receptor alpha, estrogen recep-
tor beta, and GPR30 in arteries and
veins of patients with atherosclero-
sis. Hypertension 49, 1358–1363.
Halliwell, B., and Grootveld, M. (1987).
The measurement of free radical
reactions in humans. Some thoughts
for future experimentation. FEBS
Lett. 213, 9–14.
Han, S. Z., Karaki, H., Ouchi, Y.,
Akishita, M., and Orimo, H. (1995).
17b-Estradiol inhibits Ca2+ inﬂux
and Ca2+ release induced by throm-
boxane A2 in porcine coronary
artery. Circulation 91, 2619–2626.
Harman, S. M. (2004). What do hor-
mones have to do with aging? What
does aging have to do with hor-
mones? Ann. N. Y. Acad. Sci. 1019,
299–308.
Harman,S.M. (2006). Estrogen replace-
ment in menopausal women: recent
and current prospective studies, the
WHI and the KEEPS. Gend. Med. 3,
254–269.
Hayashi, T., Yano, K., Matsui-Hirai, H.,
Yokoo, H., Hattori, Y., and Iguchi, A.
(2008). Nitric oxide and endothelial
cellular senescence.Pharmacol. Ther.
120, 333–339.
Hermenegildo, C., Garcia-Martinez, M.
C., Tarin, J. J., and Cano, A. (2002).
Inhibition of low-density lipopro-
tein oxidation by the pure antiestro-
gens ICI 182780 and EM-652 (SCH
57068). Menopause 9, 430–435.
Herrera, M. D., Mingorance, C.,
Rodriguez-Rodriguez, R., and
Alvarez de Sotomayor, M. (2010).
Endothelial dysfunction and aging:
an update. Ageing Res. Rev. 9,
142–152.
Hisamoto, K., Ohmichi, M., Kurachi,
H., Hayakawa, J., Kanda, Y., Nishio,
Y., Adachi, K., Tasaka, K., Miyoshi,
E., Fujiwara, N., Taniguchi, N., and
Murata, Y. (2001). Estrogen induces
the Akt-dependent activation of
endothelial nitric-oxide synthase in
vascular endothelial cells. J. Biol.
Chem. 276, 3459–3467.
Huang, A., Sun, D., Kaley, G., and
Koller, A. (1997). Estrogen main-
tains nitric oxide synthesis in arte-
rioles of female hypertensive rats.
Hypertension 29, 1351–1356.
Jacobson, A., Yan, C., Gao, Q., Rincon-
Skinner, T., Rivera, A., Edwards, J.,
Huang, A., Kaley, G., and Sun, D.
(2007). Aging enhances pressure-
induced arterial superoxide forma-
tion.Am. J. Physiol. Heart Circ. Phys-
iol. 293, H1344–H1350.
Johnson, B. D., Zheng, W., Korach, K.
S., Scheuer, T., Catterall, W. A., and
Rubanyi, G. M. (1997). Increased
expression of the cardiac L-type cal-
cium channel in estrogen receptor-
deﬁcient mice. J. Gen. Physiol. 110,
135–140.
Karas, R. H., Patterson, B. L., and
Mendelsohn, M. E. (1994). Human
vascular smooth muscle cells con-
tain functional estrogen receptor.
Circulation 89, 1943–1950.
Kielstein, J. T., Bode-Boger, S. M.,
Frolich, J. C., Ritz, E., Haller, H.,
and Fliser, D. (2003). Asymmetric
dimethylarginine, blood pressure,
and renal perfusion in elderly sub-
jects. Circulation 107, 1891–1895.
Kim, J., Kim, J. Y., Song, K. S., Lee, Y. H.,
Seo, J. S., Jelinek, J., Goldschmidt-
Clermont, P. J., and Issa, J. P.
(2007). Epigenetic changes in estro-
gen receptor beta gene in atheroscle-
rotic cardiovascular tissues and in-
vitro vascular senescence. Biochim.
Biophys. Acta 1772, 72–80.
Kim, J. H., Bugaj, L. J., Oh, Y. J., Bivalac-
qua, T. J., Ryoo, S., Soucy, K. G., San-
thanam, L., Webb, A., Camara, A.,
Sikka, G., Nyhan, D., Shoukas, A. A.,
Ilies,M.,Christianson,D.W.,Cham-
pion, H. C., and Berkowitz, D. E.
(2009). Arginase inhibition restores
NOS coupling and reverses endothe-
lial dysfunction and vascular stiff-
ness in old rats. J. Appl. Physiol. 107,
1249–1257.
Kim, Y. D., Chen, B., Beauregard, J.,
Kouretas, P., Thomas, G., Farhat,
M. Y., Myers, A. K., and Lees,
D. E. (1996). 17b-Estradiol pre-
vents dysfunction of canine coro-
nary endothelium and myocardium
and reperfusion arrhythmias after
brief ischemia/reperfusion. Circula-
tion 94, 2901–2908.
Kim-Schulze, S., McGowan, K. A.,
Hubchak, S. C., Cid, M. C., Martin,
M.B.,Kleinman,H.K.,Greene,G. L.,
and Schnaper, H. W. (1996). Expres-
sion of an estrogen receptor by
human coronary artery and umbili-
cal vein endothelial cells. Circulation
94, 1402–1407.
Kitazawa, T., Hamada, E., Kitazawa,
K., and Gaznabi, A. K. (1997).
Non-genomic mechanism of 17b-
oestradiol-induced inhibition of
contraction in mammalian vascu-
lar smooth muscle. J. Physiol. 499,
497–511.
Kovacic, J. C., Moreno, P., Nabel, E.
G., Hachinski, V., and Fuster, V.
(2011). Cellular senescence, vascu-
lar disease, and aging: part 2 of a
2-part review: clinical vascular dis-
ease in the elderly. Circulation 123,
1900–1910.
Kuiper,G.G.,Enmark,E.,Pelto-Huikko,
M., Nilsson, S., and Gustafsson, J. A.
(1996). Cloning of a novel recep-
tor expressed in rat prostate and
ovary. Proc. Natl. Acad. Sci. U.S.A.
93, 5925–5930.
Lakatta, E. G., and Levy, D. (2003).
Arterial and cardiac aging: major
shareholders in cardiovascular dis-
ease enterprises: part I: aging arter-
ies: a “set up” for vascular disease.
Circulation 107, 139–146.
Lamas, S., Lowenstein, C. J., and Michel,
T. (2007). Nitric oxide signaling
Frontiers in Physiology | Vascular Physiology June 2012 | Volume 3 | Article 165 | 6
Novella et al. Vascular aging in women
comes of age: 20 years and thriving.
Cardiovasc. Res. 75, 207–209.
LeBlanc, A. J., Reyes, R., Kang, L. S.,
Dailey, R. A., Stallone, J. N., Mon-
ingka, N. C., and Muller-Delp, J.
M. (2009). Estrogen replacement
restores ﬂow-induced vasodilation
in coronary arterioles of aged and
ovariectomized rats. Am. J. Phys-
iol. Regul. Integr. Comp. Physiol. 297,
R1713–R1723.
Lekontseva, O. N., Rueda-Clausen, C.
F., Morton, J. S., and Davidge, S.
T. (2010). Ovariectomy in aged
versus young rats augments matrix
metalloproteinase-mediated vaso-
constriction in mesenteric arteries.
Menopause 17, 516–523.
Lerner, D. J., and Kannel, W. B. (1986).
Patterns of coronary heart disease
morbidity andmortality in the sexes:
a 26-year follow-up of the Framing-
ham population. Am. Heart J. 111,
383–390.
Manson, J. E., Allison, M. A., Rossouw,
J. E., Carr, J. J., Langer, R. D.,
Hsia, J., Kuller, L. H., Cochrane,
B. B., Hunt, J. R., Ludlam, S. E.,
Pettinger, M. B., Gass, M., Mar-
golis, K. L., Nathan, L., Ockene,
J. K., Prentice, R. L., Robbins, J.,
and Stefanick, M. L. (2007). Estro-
gen therapy and coronary-artery cal-
ciﬁcation. N. Engl. J. Med. 356,
2591–2602.
Messerli, F. H., Garavaglia, G. E.,
Schmieder, R. E., Sundgaard-Riise,
K., Nunez, B. D., and Amodeo,
C. (1987). Disparate cardiovascular
ﬁndings in men and women with
essential hypertension. Ann. Intern.
Med. 107, 158–161.
Meyer, M. R., Prossnitz, E. R.,
and Barton, M. (2011). The G
protein-coupled estrogen receptor
GPER/GPR30 as a regulator of
cardiovascular function. Vascul.
Pharmacol. 55, 17–25.
Michel, T., and Vanhoutte, P. M. (2010).
Cellular signaling and NO produc-
tion. Pﬂugers Arch. 459, 807–816.
Miller, V. M., and Duckles, S. P. (2008).
Vascular actions of estrogens: func-
tional implications. Pharmacol. Rev.
60, 210–241.
Monsalve, E., Oviedo, P. J., Garcia-
Perez, M. A., Tarin, J. J., Cano,
A., and Hermenegildo, C. (2007).
Estradiol counteracts oxidized LDL-
induced asymmetric dimethylargi-
nine production by cultured human
endothelial cells. Cardiovasc. Res. 73,
66–72.
Moreau, K. L., Donato, A. J., Seals, D.
R., DeSouza, C. A., and Tanaka, H.
(2003). Regular exercise, hormone
replacement therapy and the age-
related decline in carotid arterial
compliance in healthy women. Car-
diovasc. Res. 57, 861–868.
Moreau, K. L., Meditz, A., Deane, K.,
and Kohrt, W. M. (2012). Tetrahy-
drobiopterin improves endothe-
lial function and decreases arte-
rial stiffness in estrogen-deﬁcient
postmenopausal women. Am. J.
Physiol. Heart Circ. Physiol. 302,
H1211–H1218.
Murphy, E. (2011). Estrogen signaling
and cardiovascular disease. Circ. Res.
109, 687–696.
Murphy, J. G., and Khalil, R. A. (1999).
Decreased [Ca2+]i during inhibition
of coronary smooth muscle contrac-
tion by 17b-estradiol, progesterone,
and testosterone. J. Pharmacol. Exp.
Ther. 291, 44–52.
Nakajima, T., Kitazawa, T., Hamada,
E., Hazama, H., Omata, M., and
Kurachi, Y. (1995). 17b-Estradiol
inhibits the voltage-dependent L-
type Ca2+ currents in aortic smooth
muscle cells. Eur. J. Pharmacol. 294,
625–635.
Novella, S., Dantas, A. P., Segarra,
G., Novensa, L., Bueno, C., Heras,
M., Hermenegildo, C., and Med-
ina, P. (2010). Gathering of aging
and estrogen withdrawal in vascu-
lar dysfunction of senescent accel-
erated mice. Exp. Gerontol. 45,
868–874.
Novella, S., Dantas, A. P., Segarra,
G., Novensa, L., Heras, M.,
Hermenegildo, C., and Medina,
P. (2011). Aging enhances contrac-
tion to thromboxane A(2) in aorta
from female senescence-accelerated
mice. Age (Dordr.). (in press).
Novensa, L., Novella, S., Medina, P.,
Segarra, G., Castillo, N., Heras,
M., Hermenegildo, C., and Dan-
tas, A. P. (2011). Aging negatively
affects estrogens-mediated effects
on nitric oxide bioavailability by
shifting ERalpha/ERbeta balance in
female mice. PLoS ONE 6, e25335.
doi:10.1371/journal.pone.0025335
Ospina, J.A.,Krause,D.N., andDuckles,
S. P. (2002). 17b-estradiol increases
rat cerebrovascular prostacyclin syn-
thesis by elevating cyclooxygenase-1
and prostacyclin synthase. Stroke 33,
600–605.
Pechenino, A. S., Lin, L., Mbai, F. N.,
Lee, A. R., He, X. M., Stallone, J.
N., and Knowlton, A. A. (2011).
Impact of aging vs. estrogen loss
on cardiac gene expression: estro-
gen replacement and inﬂammation.
Physiol. Genomics 43, 1065–1073.
Pereira, T. M., Nogueira, B. V., Lima,
L. C., Porto, M. L., Arruda, J.
A., Vasquez, E. C., and Meyrelles,
S. S. (2010). Cardiac and vascu-
lar changes in elderly atherosclerotic
mice: the inﬂuence of gender. Lipids
Health Dis. 9, 87.
Post, W. S., Goldschmidt-Clermont, P.
J., Wilhide, C. C., Heldman, A. W.,
Sussman, M. S., Ouyang, P., Mil-
liken, E. E., and Issa, J. P. (1999).
Methylation of the estrogen recep-
tor gene is associated with aging and
atherosclerosis in the cardiovascular
system.Cardiovasc. Res. 43, 985–991.
Prakash, Y. S., Togaibayeva, A. A., Kan-
nan, M. S., Miller, V. M., Fitzpatrick,
L. A., and Sieck, G. C. (1999).
Estrogen increases Ca2+ efﬂux from
female porcine coronary arterial
smooth muscle. Am. J. Physiol. 276,
H926–H934.
Prentice, R. L., Manson, J. E., Langer,
R. D., Anderson, G. L., Pettinger,
M., Jackson, R. D., Johnson, K. C.,
Kuller, L. H., Lane, D. S.,Wactawski-
Wende, J., Brzyski, R., Allison, M.,
Ockene, J., Sarto, G., and Rossouw, J.
E. (2009). Beneﬁts and risks of post-
menopausal hormone therapy when
it is initiated soon after menopause.
Am. J. Epidemiol. 170, 12–23.
Price, J. M., Hellermann, A., Heller-
mann, G., and Sutton, E. T. (2004).
Aging enhances vascular dysfunc-
tion induced by theAlzheimer’s pep-
tide beta-amyloid. Neurol. Res. 26,
305–311.
Prossnitz, E. R., and Barton, M. (2011).
The G-protein-coupled estrogen
receptorGPER in health and disease.
Nat. Rev. Endocrinol. 7, 715–726.
Register,T. C., andAdams,M. R. (1998).
Coronary artery and cultured aortic
smooth muscle cells express mRNA
for both the classical estrogen recep-
tor and the newly described estro-
gen receptor beta. J. Steroid Biochem.
Mol. Biol. 64, 187–191.
Robb, E. L., and Stuart, J. A. (2011).
Resveratrol interacts with estrogen
receptor-beta to inhibit cell replica-
tive growth and enhance stress resis-
tance by upregulating mitochondr-
ial superoxide dismutase. Free Radic.
Biol. Med. 50, 821–831.
Rodriguez-Manas, L., El-Assar, M.,
Vallejo, S., Lopez-Doriga, P., Solis,
J., Petidier, R., Montes, M., Nevado,
J., Castro, M., Gomez-Guerrero, C.,
Peiro, C., and Sanchez-Ferrer, C. F.
(2009). Endothelial dysfunction in
aged humans is related with oxida-
tive stress and vascular inﬂamma-
tion. Aging Cell 8, 226–238.
Roger, V. L., Go, A. S., Lloyd-Jones, D.
M., Adams, R. J., Berry, J. D., Brown,
T. M., Carnethon, M. R., Dai, S., de,
S. G., Ford, E. S., Fox, C. S., Fuller-
ton,H. J.,Gillespie,C.,Greenlund,K.
J., Hailpern, S. M., Heit, J. A., Ho, P.
M., Howard,V. J., Kissela, B. M., Kit-
tner, S. J., Lackland, D. T., Lichtman,
J. H., Lisabeth, L. D., Makuc, D. M.,
Marcus, G. M., Marelli, A., Matchar,
D. B., McDermott, M. M., Meigs,
J. B., Moy, C. S., Mozaffarian, D.,
Mussolino, M. E., Nichol, G., Payn-
ter, N. P., Rosamond, W. D., Sor-
lie, P. D., Stafford, R. S., Turan, T.
N., Turner, M. B., Wong, N. D.,
and Wylie-Rosett, J. (2011). Heart
disease and stroke statistics – 2011
update: a report from the American
Heart Association. Circulation 123,
e18–e209.
Rosamond, W., Flegal, K., Furie, K.,
Go, A., Greenlund, K., Haase, N.,
Hailpern, S. M., Ho, M., Howard,
V., Kissela, B., Kittner, S., Lloyd-
Jones, D., McDermott, M., Meigs, J.,
Moy, C., Nichol, G., O’Donnell, C.,
Roger, V., Sorlie, P., Steinberger, J.,
Thom, T., Wilson, M., and Hong, Y.
(2008). Heart disease and stroke sta-
tistics – 2008 update: a report from
the American Heart Association Sta-
tistics Committee and Stroke Statis-
tics Subcommittee. Circulation 117,
e25–e146.
Rossouw, J. E., Anderson, G. L., Pren-
tice, R. L., LaCroix, A. Z., Kooper-
berg, C., Stefanick, M. L., Jackson,
R. D., Beresford, S. A., Howard,
B. V., Johnson, K. C., Kotchen, J.
M., and Ockene, J. (2002). Risks
and beneﬁts of estrogen plus prog-
estin in healthy postmenopausal
women: principal results from the
women’s health initiative random-
ized controlled trial. JAMA 288,
321–333.
Rossouw, J. E., Prentice,R. L.,Manson, J.
E.,Wu, L., Barad,D., Barnabei,V. M.,
Ko, M., LaCroix, A. Z., Margolis, K.
L., and Stefanick,M. L. (2007). Post-
menopausal hormone therapy and
risk of cardiovascular disease by age
and years since menopause. JAMA
297, 1465–1477.
Rubio-Gayosso, I., Sierra-Ramirez,
A., Garcia-Vazquez, A., Martinez-
Martinez, A., Munoz-Garcia, O.,
Morato, T., and Ceballos-Reyes,
G. (2000). 17b-estradiol increases
intracellular calcium concentra-
tion through a short-term and
nongenomic mechanism in rat
vascular endothelium in culture. J.
Cardiovasc. Pharmacol. 36, 196–202.
Santhanam, L., Christianson, D. W.,
Nyhan, D., and Berkowitz, D. E.
(2008). Arginase and vascular aging.
J. Appl. Physiol. 105, 1632–1642.
Schmidt, R. J., Beierwaltes, W. H., and
Baylis,C. (2001). Effects of aging and
alterations in dietary sodium intake
on total nitric oxide production.Am.
J. Kidney Dis. 37, 900–908.
Seals,D. R., Jablonski,K. L., andDonato,
A. J. (2011). Aging and vascular
www.frontiersin.org June 2012 | Volume 3 | Article 165 | 7
Novella et al. Vascular aging in women
endothelial function in humans.
Clin. Sci. 120, 357–375.
Seely, E. W., Brosnihan, K. B., Jeune-
maitre, X., Okamura, K., Williams,
G. H., Hollenberg, N. K., and Her-
rington,D.M. (2004). Effects of con-
jugated oestrogen and droloxifene
on the renin-angiotensin system,
blood pressure and renal blood ﬂow
in postmenopausal women. Clin.
Endocrinol. (Oxf.) 60, 315–321.
Shaw,L. J.,BaireyMerz,C.N.,Pepine,C.
J., Reis, S. E., Bittner, V., Kelsey, S. F.,
Olson, M., Johnson, B. D., Mankad,
S., Sharaf, B. L., Rogers,W. J.,Wessel,
T. R.,Arant,C. B.,Pohost,G.M.,Ler-
man,A., Quyyumi,A. A., and Sopko,
G. (2006). Insights from theNHLBI-
sponsored women’s ischemia syn-
drome evaluation (WISE) study:
part I: gender differences in tra-
ditional and novel risk factors,
symptom evaluation, and gender-
optimized diagnostic strategies. J.
Am. Coll. Cardiol. 47, S4–S20.
Sherwood, A., Bower, J. K., McFetridge-
Durdle, J., Blumenthal, J. A., Newby,
L. K., and Hinderliter, A. L. (2007).
Age moderates the short-term
effects of transdermal 17b-estradiol
on endothelium-dependent vas-
cular function in postmenopausal
women. Arterioscler. Thromb. Vasc.
Biol. 27, 1782–1787.
Shi, Y., Man, R. Y., and Vanhoutte,
P. M. (2008). Two isoforms of
cyclooxygenase contribute to aug-
mented endothelium-dependent
contractions in femoral arteries of
1-year-old rats. Acta Pharmacol. Sin.
29, 185–192.
Silva-Antonialli, M. M., Fortes, Z. B.,
Carvalho, M. H., Scivoletto, R., and
Nigro, D. (2000). Sexual dimor-
phism in the response of thoracic
aorta from SHRs to losartan. Gen.
Pharmacol. 34, 329–335.
Sivritas, D., Becher, M. U., Ebrahimian,
T., Arfa, O., Rapp, S., Bohner, A.,
Mueller, C. F., Umemura, T., Wass-
mann, S., Nickenig, G., and Wass-
mann, K. (2011). Antiproliferative
effect of estrogen in vascular smooth
muscle cells is mediated by Kruppel-
like factor-4 and manganese super-
oxide dismutase. Basic Res. Cardiol.
106, 563–575.
Sobrino, A. (2011). New Expression
Pathways Regulated by Estradiol in
Human Endothelial Cells. Doctoral
Thesis. University of Valencia.
Sobrino, A., Mata, M., Laguna-
Fernandez, A., Novella, S., Oviedo,
P. J., Garcia-Perez, M. A., Tarin, J.
J., Cano, A., and Hermenegildo,
C. (2009). Estradiol stimulates
vasodilatory and metabolic path-
ways in cultured human endothelial
cells. PLoS ONE 4, e8242.
doi:10.1371/journal.pone.0008242
Sobrino, A., Oviedo, P. J., Novella, S.,
Laguna-Fernandez, A., Bueno, C.,
Garcia-Perez, M. A., Tarin, J. J.,
Cano, A., and Hermenegildo, C.
(2010). Estradiol selectively stimu-
lates endothelial prostacyclin pro-
duction through estrogen receptor-
{alpha}. J. Mol. Endocrinol. 44,
237–246.
Soloff, M. S., and Szego, C. M. (1969).
Puriﬁcation of estradiol receptor
from rat uterus and blockade of its
estrogen-binding function by spe-
ciﬁc antibody.Biochem. Biophys. Res.
Commun. 34, 141–147.
Stice, J. P., Eiserich, J. P., and Knowlton,
A. A. (2009). Role of aging versus
the loss of estrogens in the reduc-
tion in vascular function in female
rats. Endocrinology 150, 212–219.
Sumi, D., and Ignarro, L. J. (2003).
Estrogen-related receptor alpha 1
up-regulates endothelial nitric oxide
synthase expression. Proc. Natl.
Acad. Sci. U.S.A. 100, 14451–14456.
Sumino, H., Ichikawa, S., Kasama,
S., Kumakura, H., Takayama, Y.,
Sakamaki, T., and Kurabayashi,
M. (2005). Effect of transdermal
hormone replacement therapy on
carotid artery wall thickness and
levels of vascular inﬂammatory
markers in postmenopausal women.
Hypertens. Res. 28, 579–584.
Sumino, H., Ichikawa, S., Kasama,
S., Takahashi, T., Kumakura, H.,
Takayama, Y., Kanda, T., and
Kurabayashi, M. (2006). Different
effects of oral conjugated estrogen
and transdermal estradiol on arterial
stiffness and vascular inﬂammatory
markers in postmenopausal women.
Atherosclerosis 189, 436–442.
Surra, J. C., Guillen, N., rbones-Mainar,
J. M., Barranquero, C., Navarro, M.
A., Arnal, C., Orman, I., Segovia, J.
C., andOsada, J. (2010). Sex as a pro-
found modiﬁer of atherosclerotic
lesion development in apolipopro-
tein E-deﬁcient mice with different
genetic backgrounds. J. Atheroscler.
Thromb. 17, 712–721.
Taddei, S.,Virdis,A., Ghiadoni, L.,Mag-
agna, A., and Salvetti, A. (1997).
Cyclooxygenase inhibition restores
nitric oxide activity in essen-
tial hypertension. Hypertension 29,
274–279.
Taddei, S., Virdis, A., Ghiadoni, L.,
Mattei, P., Sudano, I., Bernini,
G., Pinto, S., and Salvetti, A.
(1996). Menopause is associated
with endothelial dysfunction in
women. Hypertension 28, 576–582.
Takada, Y., Kato, C., Kondo, S., Kore-
naga, R., and Ando, J. (1997).
Cloning of cDNAs encoding G
protein-coupled receptor expressed
in human endothelial cells exposed
to ﬂuid shear stress. Biochem. Bio-
phys. Res. Commun. 240, 737–741.
Tang, E. H., and Vanhoutte, P. M.
(2008). Gene expression changes of
prostanoid synthases in endothelial
cells andprostanoid receptors in vas-
cular smooth muscle cells caused
by aging and hypertension. Physiol.
Genomics 32, 409–418.
Toth, B., Scholz, C., Saadat, G., Geller,
A., Schulze, S., Mylonas, I., Friese,
K., and Jeschke, U. (2009). Estro-
gen receptor modulators and estro-
gen receptor beta immunolabelling
in human umbilical vein endothe-
lial cells. Acta Histochem. 111,
508–519.
Valverde,M.A.,Rojas, P.,Amigo, J.,Cos-
melli, D.,Orio, P., Bahamonde,M. I.,
Mann,G.E.,Vergara,C., andLatorre,
R. (1999). Acute activation of Maxi-
K channels (hSlo) by estradiol bind-
ing to the beta subunit. Science 285,
1929–1931.
Venkov, C. D., Rankin, A. B., and
Vaughan,D. E. (1996). Identiﬁcation
of authentic estrogen receptor in
cultured endothelial cells. A poten-
tial mechanism for steroid hormone
regulation of endothelial function.
Circulation 94, 727–733.
Virdis, A., Ghiadoni, L., Giannarelli, C.,
and Taddei, S. (2010). Endothelial
dysfunction and vascular disease in
later life. Maturitas 67, 20–24.
Wagner, A. H., Schroeter, M. R.,
and Hecker, M. (2001). 17beta-
estradiol inhibition of NADPH oxi-
dase expression in human endothe-
lial cells. FASEB J. 15, 2121–2130.
Wassmann, S., Baumer, A. T., Strehlow,
K., van Eickels, M., Grohe, C.,
Ahlbory, K., Rosen, R., Bohm, M.,
and Nickenig, G. (2001). Endothe-
lial dysfunction and oxidative stress
during estrogen deﬁciency in spon-
taneously hypertensive rats. Circula-
tion 103, 435–441.
Wu, Z.,Maric, C., Roesch,D. M., Zheng,
W., Verbalis, J. G., and Sandberg, K.
(2003). Estrogen regulates adrenal
angiotensin AT1 receptors by mod-
ulating AT1 receptor translation.
Endocrinology 144, 3251–3261.
Wynne, F. L., Payne, J. A., Cain, A.
E., Reckelhoff, J. F., and Khalil, R.
A. (2004). Age-related reduction
in estrogen receptor-mediated
mechanisms of vascular relax-
ation in female spontaneously
hypertensive rats. Hypertension 43,
405–412.
Xiong, Y., Yuan, L. W., Deng, H.
W., Li, Y. J., and Chen, B. M.
(2001). Elevated serum endogenous
inhibitor of nitric oxide synthase and
endothelial dysfunction in aged rats.
Clin. Exp. Pharmacol. Physiol. 28,
842–847.
Yoon, H. J., Cho, S. W., Ahn, B. W., and
Yang, S. Y. (2010). Alterations in the
activity and expression of endothe-
lial NO synthase in aged human
endothelial cells. Mech. Ageing Dev.
131, 119–123.
Yoshida, Y. I., Eda, S., and Masada,
M. (2000). Alterations of
tetrahydrobiopterin biosyn-
thesis and pteridine levels in
mouse tissues during growth and
aging. Brain Dev. 22(Suppl. 1),
S45–S49.
Zhang, F., Ram, J. L., Standley, P. R., and
Sowers, J. R. (1994). 17b-Estradiol
attenuates voltage-dependent Ca2+
currents in A7r5 vascular smooth
muscle cell line. Am. J. Physiol. 266,
C975–C980.
Zhang, Y., Stewart, K. G., and Davidge,
S. T. (2000). Estrogen replacement
reduces age-associated remodeling
in rat mesenteric arteries. Hyperten-
sion 36, 970–974.
Conﬂict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 31 January 2012; accepted: 08
May 2012; published online: 06 June
2012.
Citation: Novella S, Dantas AP, Segarra
G,Medina P andHermenegildo C (2012)
Vascular aging in women: is estrogen the
fountain of youth? Front. Physio. 3:165.
doi: 10.3389/fphys.2012.00165
This article was submitted to Frontiers
in Vascular Physiology, a specialty of
Frontiers in Physiology.
Copyright © 2012 Novella, Dantas,
Segarra, Medina and Hermenegildo.
This is an open-access article distributed
under the terms of the Creative Commons
Attribution Non Commercial License,
which permits non-commercial use, dis-
tribution, and reproduction in other
forums, provided the original authors and
source are credited.
Frontiers in Physiology | Vascular Physiology June 2012 | Volume 3 | Article 165 | 8
